Menu menu
  • Flux RSS
  • Twitter
  • Facebook
  • Google Plus
  • LinkedIn
  • YouTube

Ph. D offer with a CIFRE grant (H/F)

  • Partager
  • Imprimer

Société / Activité :


Lieu :


Poste proposé

Intitulé du poste proposé

Poste basé à
University of Evry

Nature du contrat

3 years

Nov 2019

Rémunération envisagée
De 20 000 à 30 000 euros

Détails de l’offre

Description entreprise
This thesis is funded for three years by a CIFRE contract between the SABNP laboratory (INSERM research unit UMR1204) at Genopole campus (South suburb of Paris) and the company, 4P-Pharma, a Lille biotech company addressing unmet medical needs for Human and Animal Health, from drug discovery level up to clinical phase I/II. 4P-Pharma’s strategy is to reduce the risks and costs of the early developmental of drugs by co-developing innovative projects from partners. The PhD student will also work in collaboration with Synsight, a biotech company specialized in Drug Design. Most of the work will take place in the Genopole campus. Genopole is the France’s leading biocluster for biotechnologies and research in genomics and genetics. The campus favors the developments of innovative high-tech life sciences companies and public and private research.

Description poste
Project :
The selected PhD student, through a CIFRE grant, will work on a collaborative research program between 4P-Pharma, a company expert in the development of therapeutic molecules, the SABNP lab, an INSERM unit expert in the physiopathology of RNA-Binding proteins, and Synsight, a biotech company specialized in in silico drug discovery. This project combines applied research to find new molecules to target a protein associated to neurodegenerative diseases and fundamental aspects related to splicing and RNA-protein interactions.
Context : Amyotrophic Lateral Sclerosis (ALS) is the most common adult onset neurodegenerative disease that progressively and irreversibly affects motor neurons in the brain and spinal cord. TDP-43, an RNA-Binding protein, has been identified in neuronal cytoplasmic inclusions of patients affected by ALS. This protein has a prion-like domain and regulates the splicing of mRNAs, notably of long introns in the nucleus of neurons. In addition, some mutations in TDP-43 have been associated to ALS by promoting a transition from liquid-like TDP-43-rich reversible compartments to solid-like irreversible aggregates of TDP-43.
Program :
Based on a novel technology developed in the SABNP laboratory, the PhD student will probe the liquid-liquid phase separation related to TDP-43 compartments in mammalian cells. Combined to more classical techniques, we will investigate the functions of these compartments in the splicing process in cellular models expressing TDP-43 mutations. In addition, we will screen for the effects of drugs (notably repositioned drugs) against wild-type TDP-43 and mutants.
The PhD student will use molecular biology and cellular approaches to explore the role of TDP-43 on splicing and to characterize the actions of small molecules on the formation of liquid-like compartment and splicing events controlled by TDP-43.

Developing such molecules opens novel perspectives to understand the link between the formation of TDP-43-rich liquid compartments and splicing in the nucleus and holds promises as therapeutic agents in particular for ALS and other neurodegenerative diseases associated to TDP-43.

Description profil
Candidate profile : Candidates should have a master 2 degree in July 2019 and be highly motivated individuals with knowledge in gene regulation in mammalian cells and background in Molecular and Cellular Biology. French knowledge is not required if the candidate is fluent in English. 

Niveau d’études


Personne à contacter
David Pastre



Bat Maupertuis

Code postal